MitchellVincentMathisJr.MD

Psychiatry • Columbia, MD

Pain Medicine

Physician

Join to view full profile

Are you Dr. Mathis?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
10630 Little Patuxent Pkwy
Ste 209
Columbia, MD 21044
Phone+1 410-740-8066

Fax+1 410-740-8068

Summary

Dr. Mitchell Mathis Jr., MD is a psychiatrist in Columbia, Maryland. He is currently licensed to practice medicine in Maryland.

Education & Training

National Capital ConsortiumResidency, Psychiatry/Family Medicine, 1997 - 2001
University of California Davis HealthResidency, Family Medicine, 1994 - 1997
UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1994

Certifications & Licensure

MD State Medical License 1997 - 2025
National Board of Physicians and Surgeons Family Medicine
National Board of Physicians and Surgeons Psychiatry

Publications & Presentations

PubMed

81 citations
Review of Maintenance Trials for Major Depressive Disorder: A 25-year Perspective From the US Food and Drug Administration
Silvana Borges, Yeh-Fong Chen, Thomas Laughren, Robert Temple, Hiren D. Patel
The Journal of Clinical Psychiatry. 2014-03-15
31 citations
CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients: Basis for the US Food and Drug Administration’s New Dosing Recommendations
Hobart Rogers, Atul Bhattaram, Issam Zineh, Jogarao V. S. Gobburu, Mitchell V. Mathis
The Journal of Clinical Psychiatry. 2012-09-15
18 citations
The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration
Mathangi Gopalakrishnan, Hao Zhu, Tiffany Farchione, Mitchell V. Mathis, Mehul Mehta
The Journal of Clinical Psychiatry. 2020-03-03

Press Mentions

The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive DyskinesiaNovember 15th, 2020
Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in the Journal of the American Medical AssociationNovember 23rd, 2019
Acadia Pharmaceuticals: This Is Not a Pharmaceuticals CompanyJuly 9th, 2018
Join now to see all